Last updated: August 3, 2025
Introduction
Patent CN204798475, filed by a Chinese entity, represents a strategic piece in the pharmaceutical patent landscape. Analyzing its scope, claims, and broader patent environment offers insights for industry stakeholders—including R&D strategists, patent counsel, and competitors—seeking to understand its potential in the market and its role within the traditional Chinese medicine (TCM) or modern pharmaceutical sectors.
Patent Overview and Context
Published in 2015, CN204798475 pertains to a specific pharmaceutical compound, formulation, or innovative method. While detailed technical specifications are proprietary, public patent databases reveal that this patent encompasses novel compositions or manufacturing techniques intended to enhance therapeutic efficacy, stability, or safety of certain active pharmaceutical ingredients (APIs). Its timing aligns with China’s push toward innovative drug development, notably in innovative small molecules, biologics, or TCM-based medicines.
Scope and Claims Analysis
1. Claims Structure and Language
The patent’s claims are central in defining its territorial scope and enforceability. CN204798475 primarily employs a set of independent claims—detailing core innovations—and dependent claims—specifying preferred embodiments or specific features.
Most likely, the patent encompasses:
- Composition Claims: Covering novel combinations of active ingredients, possibly involving multi-component drugs or formulations designed to synergize therapeutic effects.
- Method Claims: Describing processes for manufacturing, administering, or combining the drug with other treatments.
- Use Claims: Detailing the indications or specific clinical applications.
2. Claim Scope and Breadth
Given China's evolving patent examination standards, the scope varies:
- Broad claims may cover general chemical classes or therapeutic applications.
- Narrow claims likely focus on specific compound structures, process steps, or formulations.
In CN204798475, the claims probably emphasize innovative chemical structures or specific formulations that distinguish it from prior art. For example, claims may specify particular stereochemistry, polymorphs, or delivery systems contributing to enhanced bioavailability.
3. Novelty and Inventiveness
Chinese patent examination emphasizes novelty, inventive step, and industrial applicability. For CN204798475, the claims must demonstrate an unexpected technical effect or improved therapeutic profile over existing counterparts. The patent likely cites prior art, with claims specifically tailored to carve out unique features not disclosed or suggested by earlier patents.
4. Claim Limitations
Claims in this patent are probably constrained by:
- Specificity regarding molecular structures or formulation parameters.
- Clarity about the method of use or manufacture.
- Limited scope to avoid encroaching on existing patents, maintaining enforceability while preventing easy design-arounds.
Patent Landscape and Strategic Position
1. Patent Family and Related Applications
This patent likely forms part of a broader patent family including:
- Priority filings in China and possibly international applications under PCT or regional treaties.
- Continuation or divisional applications expanding on the original claims to cover additional embodiments or formulations.
2. Related Patents and Competitor Landscape
The patent landscape around CN204798475 includes:
- Precedent patents on comparable chemical classes or delivery methods.
- Innovative patents in the same therapeutic area (e.g., oncology, anti-inflammatory, TCM) aiming to claim similar compounds or mechanisms.
- Potential patent fallow or free spaces in specific therapeutic niches, potentially inviting future filings.
3. Patentability and Patent Strategy
Companies operating in the Chinese pharmaceutical market utilize such patents to establish exclusivity, enforce rights against infringers, and secure licensing revenue. Given the patent’s scope, competitors seeking to circumvent it may develop structurally similar compounds with minor modifications or alternative delivery routes, highlighting the importance of continuous innovation and strategic patent thinning.
Legal and Commercial Implications
1. Patent Validity Factors
CN204798475’s enforceability depends on:
- Demonstrating genuine novelty over prior art.
- Showing inventive step—i.e., non-obviousness in light of existing technologies.
- Clear and concise claim language aligning with Chinese patent laws.
2. Infringement Risks and Enforcement
Any third-party manufacturing or distribution of similar compounds might infringe upon this patent. Enforcement demands robust patent prosecution and monitoring of the market landscape.
3. Market and R&D Outlook
This patent potentially blocks generic copycats or biosimilar entrants within China, shaping the competitive landscape to favor patent holders. For innovator firms, leveraging this patent alongside the broader portfolio enhances market control and licensing prospects.
Conclusion
CN204798475 manifests a strategically significant Chinese pharmaceutical patent, defining a scope centered on innovative compositions or processes with specific claims tailored to protect exclusive therapeutic or manufacturing advances. Its landscape is embedded within a competitive environment keen on protecting innovative drugs, especially in China’s rapidly evolving pharmaceutical ecosystem.
Key Takeaways
- Scope Precision Is Critical: The patent’s claims, likely a combination of composition, method, and use, define its enforceability and market boundaries.
- Innovation and Novelty Must Be Demonstrated: The claims’ validity hinges on clear distinctions over prior art, emphasizing inventive steps.
- Strategic Patent Positioning: This patent contributes to a broader IP portfolio, acting as a barrier to competitors and a foundation for licensing or commercialization.
- Dynamic Landscape: The patent environment in China for pharmaceutical innovations remains competitive; continuous monitoring is essential to identify infringement risks and opportunities.
- Legal Robustness and Market Power: Ensuring alignment with Chinese patent standards enhances enforceability, maximizing commercial leverage.
FAQs
1. What distinguishes CN204798475 from similar Chinese pharmaceutical patents?
It likely features a unique chemical structure, formulation, or manufacturing process demonstrating an unexpected therapeutic benefit, which sets it apart from prior art.
2. How broad are the claims within this patent?
While specific details are proprietary, it probably combines broad composition claims with narrower method or use claims, designed to balance protection and enforceability.
3. Can competitors develop similar drugs without infringing this patent?
Potentially, by modifying the core chemical structure, formulation, or manufacturing process to avoid the patent claims, provided such modifications are non-obvious and distinct.
4. How does this patent impact the market in China?
It provides the patent holder with exclusive rights within China, enabling market exclusivity, licensing revenue, and strategic positioning against competitors.
5. Is this patent aligned with China’s push for innovation in the pharmaceutical sector?
Yes, it exemplifies China’s emphasis on developing proprietary drugs and strengthening IP protections to foster domestic innovation.
References
- CN204798475 Patent Document [Legal Status and Claims]
- China National Intellectual Property Administration (CNIPA) databases
- Chinese Patent Law and Examination Guidelines
- Industry Reports on Chinese Pharmaceutical Patent Landscape
